top of page

Home

BiotechTV U

Company News

Bright Minds

Tech + Tours

GSK's Emma Walmsley on the company's pipeline, business development, AI, UK life sciences, and more | 04/30/24

Play Video

TOP VIDEO: GSK's Emma Walmsley on the company's pipeline, business development, AI, UK life sciences, and more | 04/30/24

Latest Videos

Autobahn Therapeutics announced a $100M series C financing this week as it prepares to move its thyromimetic into phase 2 | 07/26/24

Play Video

Company News:
Autobahn Therapeutics announced a $100M series C financing this week as it prepares to move its thyromimetic into phase 2

07/26/2024

HSBC 1H2024 Venture Healthcare Report

Play Video

HSBC 1H 2024 Venture Healthcare Report: Jonathan Norris discusses venture trends from the first half.

Download the report

Sponsored

Bessemer Venture Partners' Morgan Cheatham shares his take on AI in life sciences | 07/25/24

Play Video

AI x Bio Summit:

Bessemer Venture Partners' Morgan Cheatham shares his take on AI in life sciences

7/25/2024

The Co-Founder of Kernal Bio describes designing mRNA therapies that are selectively delivered and expressed by specific location | 07/25/24

Play Video

AI x Bio Summit:

Kernal Bio's CEO describes designing mRNA therapies that are selectively delivered to, and translated by, specific cells in the body

7/25/2024

Generate Biomedicines' CEO Mike Nally gives an update on the company's clinical and emerging programs | 07/25/24

Play Video

AI x Bio Summit:

Generate Biomedicines' CEO Mike Nally gives an update on the company's clinical and emerging programs

7/25/2024

Winner:

2024 European Mediscience Awards

Immunocore's CEO on KIMMTRAK sales and expanding into PRAME, autoimmune and more | 01/08/24

12:48

Immunocore's CEO on KIMMTRAK sales and expanding into PRAME, autoimmune and more | 01/08/24

Bahija Jallal talks about the experience Immunocore has gained commercializing KIMMTRAK since its 2022 approval and into what areas she hopes to expand the company's development.

Recursion's Chris Gibson on the potential utility of machine learning and AI in drug development | 01/11/24

16:01

Recursion's Chris Gibson on the potential utility of machine learning and AI in drug development | 01/11/24

Chris Gibson describes the new technologies that are accelerating and refining drug development, shares best practices, and elaborates on Recursion's partnerships.

Alnylam CEO Yvonne Greenstreet previews 2024, including HELIOS-B | 01/09/23

14:40

Alnylam CEO Yvonne Greenstreet previews 2024, including HELIOS-B | 01/09/23

Yvonne Greenstreet talks about how Alnylam has been moving RNAi beyond the liver and previews the year ahead, including HELIOS-B.

Altimmune CEO Vipin Garg explains the science of weight loss drugs and makes the case for GLP-1/glucagon | 01/10/24

11:10

Altimmune CEO Vipin Garg explains the science of weight loss drugs and makes the case for GLP-1/glucagon | 01/10/24

Vipin Garg explains the theory of how GLP-1 cause weight loss and gives the rationale for adding glucagon agonism for added effect.

A deep dive into antibody-drug conjugates with Daiichi Sankyo's Ken Keller | 01/10/24

11:18

A deep dive into antibody-drug conjugates with Daiichi Sankyo's Ken Keller | 01/10/24

Ken Keller describes recent advances in ADC technology, talks about the recent Merck deal, and what it was like to change breast cancer at ASCO in 2022.

Biotech veteran Harvey Berger on why he joined Kojin Therapeutics | 01/10/24

10:41

Biotech veteran Harvey Berger on why he joined Kojin Therapeutics | 01/10/24

Harvey Berger describes the science of ferroptosis and his experience working with Kojin's scientific founder Stuart Schreiber. He also shares a few memories of the beginnings of the biotech sector.

Tarsus' CEO on the launch XDEMVY and additional programs that will be reading out in 2024 | 01/10/24

16:19

Tarsus' CEO on the launch XDEMVY and additional programs that will be reading out in 2024 | 01/10/24

Bobby Azamian provides an update on the commercial launch of XDEMY in demodex blepharitis, and discusses programs for meibomian gland disease, rosacea, and Lyme disease.

Mammoth Biosciences' Trevor Martin on using ultra-compact CRISPR systems to go after extra-hepatic indications in-vivo | 01/11/24

11:18

Mammoth Biosciences' Trevor Martin on using ultra-compact CRISPR systems to go after extra-hepatic indications in-vivo | 01/11/24

Trevor Martin describes how Mammoth is working on the evolution of CRISPR to help make it more versatile for potential use in broad in-vivo applications.

2024 SF Healthcare Week

Moderna CEO Stéphane Bancel walks us through Moderna and Merck's 3-year individual neoantigen therapy + Keytruda adjuvant melanoma data | 06/03/24

05:57

Moderna CEO Stéphane Bancel walks us through Moderna and Merck's 3-year individual neoantigen therapy + Keytruda adjuvant melanoma data | 06/03/24

At Moderna's analyst meeting at #ASCO24 in Chicago, Stéphane Bancel shows the Kaplan-Meier curve separation over time for the neoantigen platform in melanoma, and also discusses Moderna's intratumoral platform, and how mRNA can work with new modalities like bispecifics and cell therapies

The CEO of IDRx describes early GIST data at ASCO24 that he believes could point to a best-in-class asset | 06/03/24

11:50

The CEO of IDRx describes early GIST data at ASCO24 that he believes could point to a best-in-class asset | 06/03/24

Tim Clackson explains how IDRX-42 has been designed to eliminate resistance mutations that the current standard of care cannot handle, and discusses P1/b ORR data presented at ASCO today.

ApexOnco's Madeleine Armstrong gives a recap of #ASCO24 highlights | 06/03/24

13:43

ApexOnco's Madeleine Armstrong gives a recap of #ASCO24 highlights | 06/03/24

Madeleine Armstrong gives her take on data from Caribou, Summit, Daiichi Sankyo, GSK, Abbvie, and more.

ApexOnco's Jacob Plieth previews #ASCO24 | 05/31/24

19:23

ApexOnco's Jacob Plieth previews #ASCO24 | 05/31/24

From McCormick Place, Jacob Plieth previews key data from Merus, Summit, Iovance, Caribou, AstraZeneca, GSK, Gilead, and more.

The CEO of Cullinan Therapeutics discusses two data sets at #ASCO24 and the rationale for a T-cell engager for autoimmune disease | 06/01/24

14:06

The CEO of Cullinan Therapeutics discusses two data sets at #ASCO24 and the rationale for a T-cell engager for autoimmune disease | 06/01/24

Nadim Ahmed describes #ASCO24 data from today for CLN-619 and zipalertinib, and discusses taking a CD19/CD3 into the clinic for lupus.

Summit Therapeutics' Jack West on the company's PD-1xVEGF bi-specific vs Keytruda news | 06/01/24

16:02

Summit Therapeutics' Jack West on the company's PD-1xVEGF bi-specific vs Keytruda news | 06/01/24

V.P. of Clinical Operations Jack West gives his interpretation of the announcement that Summit's partner Akeso made in China that it beat Keytruda on PFS head-to-head in 1L lung. He shares his opinion of how this data could translate outside of China and what Summit's development plans are currently.

Nimbus Therapeutics CEO Jeb Keiper on the company's HPK1 data at #ASCO24 | 06/01/24

10:58

Nimbus Therapeutics CEO Jeb Keiper on the company's HPK1 data at #ASCO24 | 06/01/24

Jeb Keiper describes the HKP1 pathway and why he believes his company's expertise in precision engineering and machine learning has helped it discover and develop this asset.

Rachel Haurwitz on Caribou's #ASCO24 data and the rationale for taking time to look further at HLA matching for allo CAR-T | 06/03/24

15:15

Rachel Haurwitz on Caribou's #ASCO24 data and the rationale for taking time to look further at HLA matching for allo CAR-T | 06/03/24

Rachel Haurwitz elaborates on the data update for CB-010 that was presented at ASCO yesterday and describes why the company will push back the start of a pivotal trial approximately six months to better understand how HLA matching potentially affects efficacy.

#ASCO24

Recapping #ASH23 with Syndax CEO Michael Metzger | 12/12/23

25:14

Recapping #ASH23 with Syndax CEO Michael Metzger | 12/12/23

Syndax's CEO reviews late breaking data on the menin inhibitor revumenib in KMT2A-rearranged leukemias and discusses axatilimab's GvHD data.

Pyruvate kinase activation as a sickle cell disease strategy with Agios' CEO at #ASH23 | 12/11/23

11:20

Pyruvate kinase activation as a sickle cell disease strategy with Agios' CEO at #ASH23 | 12/11/23

Brian Goff highlights data from the phase 2 portion of the RISE UP pivotal study of Mitapivat for SCD that was presented at #ASH23 today.

Gracell's founder explains his company's rationale for BCMA + CD19 in both myeloma and lupus | 12/11/23

20:20

Gracell's founder explains his company's rationale for BCMA + CD19 in both myeloma and lupus | 12/11/23

William Cao describes how the same product might be used for cancer and lupus, explains the idea behind FasTCAR manufacturing, and gives his thoughts on the CAR-T market in China.

Talking BTK degraders with the CEO of Nurix Therapeutics at #ASH23 | 12/11/23

13:08

Talking BTK degraders with the CEO of Nurix Therapeutics at #ASH23 | 12/11/23

Arthur Sands elaborates on two programs Nurix presented updated data for at ASH and dives into the company's pipeline and partnerships.

Kicking off Monday (Day 3) of the ASH Annual Meeting with ApexOnco's Jacob Plieth | 12/11/23

16:39

Kicking off Monday (Day 3) of the ASH Annual Meeting with ApexOnco's Jacob Plieth | 12/11/23

Jacob Plieth shares his thoughts on MorphoSys, Syndax, Poseida, Arcellx, Autolus, Cogent, Dizal, and more.

Mass General's Marcela Maus talks about the latest in CAR-T at #ASH23 | 12/10/23

08:04

Mass General's Marcela Maus talks about the latest in CAR-T at #ASH23 | 12/10/23

Dr. Maus comments on CD19 lupus data, the recent FDA note on malignancies, the work her lab is doing for brain and heme cancers, and things she has seen of interest at ASH.

Poseida's soon-to-be CEO on this mornings allo BCMA CAR-T data at #ASH23 | 12/10/23

15:04

Poseida's soon-to-be CEO on this mornings allo BCMA CAR-T data at #ASH23 | 12/10/23

Kristin Yarema elaborates on Poseida's ASH data, describes how she believes that honing in on the right preconditioning regimen might be the success factor, and highlights next steps.

Vertex COO Stuart Arbuckle on the approval and launch of CASGEVEY for sickle cell disease | 12/10/23

10:43

Vertex COO Stuart Arbuckle on the approval and launch of CASGEVEY for sickle cell disease | 12/10/23

Stuart Arbuckle describes the approval and launch dynamics of this gene-edited cell therapy, describes who it is for, and comments on the possible long-term direction of the field.

#ASH23

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Breakthrough Properties is a life science real estate company that is exclusively focused on delivering cutting-edge environments for the life science industry. With a portfolio of roughly 5 million square feet across the US, UK and continental Europe, Breakthrough has emerged as a leading partner for high-growth biotechs and pharmas around the world.

Visit Breakthrough Properties

bottom of page